Prevymis (letermovir) - Merck (MSD)
Letermovir Prophylaxis and Risk of Bacterial or Fungal Infection after Allogeneic Hematopoietic Cell Transplantation. (PubMed, J Infect Chemother) - Dec 11, 2025 - "LTV prophylaxis significantly reduced the risk of bacteremia. However, it was not associated with the risk of invasive fungal infections." 
Journal • Acute Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Transplantation
http://www.ncbi.nlm.nih.gov/pubmed/41371495
 
Hirohisa Nakame; Hiroki Hosoi; Keiji Okinaka; Kimikazu Yakushijin; Makoto Onizuka; Makoto Yoshimitsu; Marie Ohbiki; Masatsugu Tanaka; Naoki Kurita; Naoyuki Uchida; Noboru Asada; Noriko Doki; Shun-Ichi Kimura; Shunto Kawamura; Takahiro Fukuda; Takashi Toya; Tetsuya Eto; Tetsuya Nishida; Yoshiko Atsuta; Yoshinobu Kanda; Yuta Hasegawa
 
Dec 11, 2025
 
Prev Next